FCGR2A and rheumatoid arthritis: Importantly, there is recent evidence that the association between FCGR2A and the clinical response in RA could be dependent on the type of anti-TNF agent, with a significant association in patients treated with infliximab [25,26] and a lack of association on etanercept-treated patients [26,27].